TY - JOUR T1 - P294 Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with copd classified as gold b JF - Thorax JO - Thorax SP - A272 LP - A273 DO - 10.1136/thoraxjnl-2016-209333.473 VL - 71 IS - Suppl 3 A2 - , Y1 - 2016/12/01 UR - http://thorax.bmj.com/content/71/Suppl_3/A272.5.abstract N2 - R Buhl reports financial support to his institution from Boehringer Ingelheim during the conduct of the study and, outside of the submitted work, financial support from Boehringer Ingelheim, AstraZeneca, Chiesi, Novartis, Teva, Roche and GlaxoSmithKline for attendance at advisory boards and speaking activities, and research support to his institution from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Roche.L McGarvey reports personal fees from Applied Clinical Intelligence during the conduct of the study, and grants from Asthma UK, NI Chest Heart & Stroke, NC3Rs, British Heart Foundation and Chiesi, and other from Boehringer Ingelheim, GlaxoSmithKline, Chiesi, Almirall and NAPP outside the submitted work.S Korn has received grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Takeda, grants from Teva and MedImmune, and personal fees from Almirall and Grifols.GT Ferguson, during the conduct of the study, reports grants, personal fees and non-financial support from Boehringer Ingelheim and, outside the submitted work, grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees from GlaxoSmithKline, grants and personal fees from Novartis, AstraZeneca, Pearl Therapeutics and Sunovion, and grants from Forest.L Grönke, C Hallmann and F Voß are employees of Boehringer Ingelheim Pharma GmbH & Co. KG.KF Rabe reports financial for support for consultancy work from AstraZeneca, Chiesi, Novartis, MSD and GlaxoSmithKline, and grants from Altana, Novartis, AstraZeneca, MSD and Nycomed.F Maltais reports financial support from Boehringer Ingelheim during the conduct of the study and, outside of the submitted work, financial support from Boehringer Ingelheim and GlaxoSmithKline for attendance at advisory boards, financial support from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and Novartis for speaking activities, and research support from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Nycomed and Novartis. ER -